Study of Apatinib and Capecitabine Combination to Maintain Treating Metastatic Colorectal Cancer

Sponsor
Yanqiao Zhang
Study ID
NCT03132025
Phase
PHASE2
Status
Unknown

Conditions

  • Metastatic Colorectal Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • "Apatinib" and "Capecitabine" — DRUG
    Combine "Apatinib" and "Capecitabine" to Maintain Treating Metastatic Colorectal Cancer
  • "Capecitabine" — DRUG
    Single Drug "Capecitabine" to Maintain Treating Metastatic Colorectal Cancer

Study Details

To control apatinib and capecitabine combination to maintain treating metastatic colorectal cancer.

Key Dates

Start date
Apr 30, 2017
Status verified
Apr 2017
Primary completion
Feb 28, 2018
Completion
Apr 30, 2018

Study Design

Enrollment
40 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: A: "apatinib" and "capecitabine"
    Arm A: "apatinib" and "capecitabine" apatinib 250mg qdpo; capecitabine 1000mg/m2 qdpo d1-14 q3w
  • Active Comparator: B: "capecitabine" single drug
    Arm B: "capecitabine" single drug "capecitabine" 1000mg/m2 qdpo d1-14 q3w

Primary Outcome Measure

Progression-free Survival of Patients with Apatinib and Capecitabine Combination That is prolonged [ Time Frame: up to 10 months ]

Related Studies